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Abstract
Objective—To estimate the frequency of severe maternal morbidity, assess its underlying
etiologies, and develop a scoring system to predict its occurrence.
Methods—This was a secondary analysis of a National Institute of Child Health and Human
Development Maternal-Fetal Medicine Units Network cohort of 115,502 women and their
neonates born in 25 hospitals across the United States over a 3-year period. Women were
classified as having severe maternal morbidity according to a scoring system that takes into
account the occurrence of red blood cell transfusion (> 3 units), intubation, unanticipated surgical
intervention, organ failure, and intensive care unit admission. The frequency of severe maternal
morbidity was calculated and the underlying etiologies determined. Multivariable analysis
identified patient factors present on admission that were independently associated with severe
maternal morbidity, these were used to develop a prediction model for severe maternal morbidity.
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Results—Among 115,502 women who delivered during the study period, 332 (2.9 per thousand
births, 95% CI 2.6 – 3.2) experienced severe maternal morbidity. Postpartum hemorrhage was
responsible for approximately half of severe maternal morbidity. Multiple patient factors were
found to be independently associated with severe maternal morbidity and were used to develop a
predictive model with an area under the receiver-operating characteristic curve of 0.80.
Conclusion—Severe maternal morbidity occurs in approximately 2.9 per 1000 births, is most
commonly due to postpartum hemorrhage, and occurs more commonly in association with several
identifiable patient characteristics.
After years of decline, the frequency of maternal mortality in the United States has begun to
increase.1 Consequently, several professional organizations devoted to maternal health held
a meeting in 2012 to determine methods to help improve maternal outcomes.2 One concern
was the lack of a standardized metric to identify women who experience significant maternal
morbidity. This absence hinders both: (1) investigation into etiologies of the events that
result in severe morbidity, and (2) evidence-based quality improvement initiatives.
Correspondingly, the group called for research that would help to develop a standardized
measure of severe maternal morbidity that could be used as the foundation for surveillance
and continuous quality improvement.
The development of such a measure is a goal that has been shared by others. Geller et al 3
identified those with very severe morbidity by validating an arithmetical scoring system that
took into account whether a woman had an unanticipated surgical intervention, was
intubated for more than 12 hours postpartum, received a transfusion more than 3 units, was
admitted to the intensive care unit (ICU), or experienced organ failure. However, this
measure only has been explored in two studies, both of which were performed in single
centers with relatively few patients analyzed.4,5
The purpose of the present study was to estimate the frequency of severe maternal morbidity
in a large multi-center obstetric population using the system of Geller et al,4 and to identify
its underlying etiologies, associated factors, and whether a scoring system could be
developed to predict its occurrence.
Methods
Between 2008 and 2011, investigators at 25 medical centers, belonging to the Eunice
Kennedy Shriver National Institute of Child Health and Human Development Maternal-Fetal
Medicine Units Network, assembled an obstetric cohort in which detailed information was
collected by trained and certified nurses on patient characteristics, intrapartum events,
pregnancy outcomes, and postpartum courses of women who delivered at their institutions.
Full details of the study design and technique of data collection for the Assessment of
Perinatal EXcellence (APEX) cohort have been described previously.6 Institutional review
board approval was obtained at all centers under a waiver of informed consent.
The present analysis included all women in the APEX cohort. Women were given a score
according to the classification system developed by Geller et al.4 This system assigns points
according to whether a parturient had an unanticipated surgical intervention (1 point), was
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intubated for more than 12 hours (2 points), received a red blood cell transfusion of greater
than 3 units (3 points), was admitted to the intensive care unit (4 points), or had failure of at
least one organ system (5 points). Points are then summated, and those women with 8 or
more points are classified as having had severe morbidity. For the present analysis, organ
failure was defined as any one of the following: cardiopulmonary arrest, cardiac dysfunction
(e.g., cardiomyopathy), adult respiratory distress syndrome (ARDS), pulmonary edema,
disseminated intravascular coagulation (DIC), transfusion of platelets, stroke, subdural
hematoma, postpartum serum creatinine > 2.0 or postpartum serum AST/SGOT > 1000.
Also, women were considered to fulfill the intubation criterion if they were intubated on at
least one day, given that data for length of intubation were collected in day, not hour,
increments.
Women who experienced severe morbidity were identified and the overall frequency in the
cohort was determined. Their abstracted data were further reviewed by one of the
investigators (WAG) to determine the primary etiology of their morbid outcome. Etiologic
categories included: hemorrhage, infection, hypertensive disorders of pregnancy, non-
hypertensive and non-infectious cardiopulmonary complications, trauma, iatrogenic
complications, and pre-existing maternal medical conditions.
We then investigated which patient factors were independently associated with severe
morbidity using multivariable logistic regression to generate odds ratios and 95% confidence
intervals. Model selection and internal validation was performed using k-fold cross-
validation in which the cohort was randomly divided into 10 equal parts and logistic
regression models, using backward selection, were generated using every possible
combination of 9 of the 10 sets.7 Variables with P <.05 were retained, and each of the 10
sub-samples was used for validation. A risk score was developed using methods similar to
Rassi et al.8 Each coefficient from the final multivariable model was divided by the smallest
coefficient and rounded to the nearest integer. The area under the receiver-operating
characteristic curve (AUC), sensitivity, specificity, and positive and negative likelihood
ratios (with 95% confidence intervals) were then calculated. All tests were two-tailed and P
< .05 was used to define statistical significance. No imputation for missing data was
performed. Analyses were performed using SAS software (SAS Institute, Cary, NC).
Results
During the study period, 115,502 women delivered. After excluding 7 maternal deaths,
115,495 were included in this analysis. Of the 115,495, 0.5% (N = 619) had an unanticipated
surgical intervention, 0.1% (N = 136) were intubated on at least one day, 0.3% (N = 323)
received a blood transfusion of at least 3 units, 0.6% (N = 735) were admitted to the
intensive care unit, and 0.6% (N = 709) had at least one organ system fail. The summative
point totals, as determined by the system of Geller et al, 4 are provided in Table 1. Three
hundred and thirty-two women (2.9 per thousand births, 95% CI 2.6 – 3.2) had a point total
of 8 or more and thus were classified as having had severe morbidity.
Postpartum hemorrhage was responsible for almost half of severe morbidity (n = 158,
47.6%). Hypertensive complications (n = 68, 20.5%), acute cardiopulmonary complications
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(cardiomyopathy, arrest, acute respiratory distress syndrome, pulmonary edema) (n = 63,
19.0%), infection (n = 20, 6.0%), pre-existing maternal medical conditions (n = 8, 2.4%),
venous thromboembolism (n = 4, 1.2%), trauma (n = 4, 1.2%), acute neurologic
complications (n = 3, 0.9%), iatrogenic events (anaphylaxis, surgical visceral injury)(n = 2,
0.6%), and pregnancy-specific conditions (acute fatty liver, amniotic fluid embolism) (n = 2,
0.6%) accounted for the remainder.
Patient characteristics, stratified by the occurrence of severe morbidity, are presented in
Table 2. Patient factors significantly and independently associated with severe morbidity,
along with odds ratios and 95% confidence intervals, are presented in Table 3. The presence
of placenta accreta was the characteristic most strongly associated with severe morbidity,
although multiple other associated factors, such as preterm delivery, antenatal anticoagulant
or cigarette use, hypertension, diabetes mellitus, abruptio placentae, and prior cesarean
delivery also were identified.
The number of points that each characteristic contributed to the risk score are presented in
Table 3. Point totals ranged from 0 to 24, with higher point totals indicating greater
frequency of severe maternal morbidity (Table 4). The AUC for the risk score model was
0.80 (95%CI, 0.77–0.83). Sensitivity, specificity, and likelihood ratios for the various risk
score cutoff points are also presented (Table 4).
Discussion
In this study, we have used the scoring system developed by Geller et al. 4 to characterize
the frequency and factors associated with severe morbidity in a 25-hospital consortium. 6
Our results demonstrate that, between 2008 and 2011, severe morbidity occurred in 2.9 per
thousand woman who gave birth. Postpartum hemorrhage and hypertensive disorders of
pregnancies together accounted for more than two-thirds of the primary underlying causes of
severe morbidity. Additionally, the probability of experiencing severe morbidity was related
to multiple well-defined patient characteristics.
The observed frequency is slightly lower than that estimated in other reports from developed
countries. Wen et al, 9 using Canadian administrative data, found that severe maternal
morbidity occurred in 0.44% of deliveries. Zwart et al, 10 analyzing data from a prospective
study between 2004 and 2006, estimated that 0.71% of women giving birth experienced
severe maternal morbidity in the Netherlands. Callaghan et al11 studied the National
Inpatient Sample to estimate severe maternal morbidity among American women and
derived an estimate of 1.5% for the years 2008–2009.
These previous studies differ from the current analysis in several important aspects. Both the
Canadian and American estimates were derived from administrative data sets, in which the
codes are both limited in their scope, entered primarily for billing, and as Callaghan et al
note, subject to errors of omission and commission.9,11 Also, the definition of severe
morbidity in all of these studies was based on the occurrence of a pre-defined event, such as
eclampsia or blood transfusion.9–11 However, determining morbidity through such a system
could miss women who had severe morbidity because of other diagnoses or causes. These
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approaches also may be too sensitive; even though it is likely that a woman who has
received a blood transfusion has experienced some morbidity, it may not have been severe.
Our analysis, in contrast, estimated the frequency of severe morbidity from a dataset that
was derived from direct chart abstraction and was specifically constructed for research
purposes. We used a system that was developed and validated specifically for the purpose of
identifying women with the gravest obstetric morbidity. This system is not dependent on any
single factor or diagnosis for identification, but on a constellation of adverse outcomes that
could be the end result of any serious untoward or precipitating event.
The use of such a system allows insight into the etiologies that are contributing to severe
morbidity. Such knowledge is important from a public health perspective in terms of
knowing where to focus prevention and treatment efforts. Our data support the concept that
postpartum hemorrhage and hypertensive disease of pregnancy are responsible for a large
portion of severe maternal morbidity, and underscore that the continued pursuit of best-
practice care for these conditions may also yield substantial benefits in terms of decreasing
the most severe maternal outcomes.12,13
Our data also allow insight into the patient factors that are associated with severe morbidity.
These factors, as well as the risk score derived from them, could be used to help quantify the
level of risk a woman has for a severely morbid outcome. It should be noted, however, that
this quantification does not allow precise identification of women who will and will not
have severe maternal morbidity. Because of the very low prevalence of severe morbidity, as
indicated by Table 4, even with a prediction system with an ROC of 0.80, a cutoff point that
identifies women with a high risk of severe morbidity will simultaneously miss identifying
most women who experience severe morbidity. For example, although a score of at least 19
results in a positive predictive value for severe maternal morbidity of 39%, this cutoff will
not identify 93% of women who will experience severe morbidity. Conversely, a cutoff of 5
will result in 67%of women destined to have severe maternal morbidity being identified, but
a positive predictive value of only 0.93%. Thus, it is not evident that this prediction model
could be used to effectively identify and change the clinical care of individual women.
Nevertheless, as maternal morbidity and mortality increase in frequency in the United
States, the need to better understand their risks and causes increases in importance. Without
the ability to measure and analyze these outcomes, the potential for systems improvement is
compromised.2 Severe morbidity as defined in this analysis, was approximately 50 times as
frequent as maternal mortality in our population and could be used more readily to track
outcomes and to be incorporated into quality improvement initiatives. Our analysis
illustrates the importance of gaining a national consensus on a standard definition of severe
maternal morbidity in order to allow standardized surveillance.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Table 2
Patient Characteristics by Severe Maternal Morbidity*
No. (%) in Patients With Severe
Maternal Morbidity, n=332





 < 35 232 (69.9) 95914 (83.3)
 ≥35 100 (30.1) 19242 (16.7)
Race/ethnicity‡ <0.001
 Non-Hispanic White 114 (34.3) 51922 (45.1)
 Non-Hispanic Black 110 (33.1) 23761 (20.6)
 Non-Hispanic Asian 22 (6.6) 5976 (5.2)
 Hispanic 66 (19.9) 27224 (23.6)
 Other 16 (4.8) 5067 (4.4)
 Not documented 4 (1.2) 1206 (1.1)
Body mass index at delivery, kg/m2 <0.001
 < 25 44 (13.5) 14198 (12.6)
 25–29.9 102 (31.4) 41160 (36.5)
 30–34.9 79 (24.3) 32006 (28.4)
 35–39.9 44 (13.5) 15041 (13.3)
 ≥40 56 (17.2) 10423 (9.2)
Cigarette use during pregnancy 57 (17.2) 11308 (9.8) <0.001
Cocaine or methamphetamine use during pregnancy 9 (2.7) 821 (0.7) <0.001
Insurance status <0.001
 Non-government assisted 159 (48.3) 69284 (60.7)
 Government-assisted 170 (51.7) 44949 (39.4)
Prenatal care 284 (96.6) 107213 (97.9) 0.11
Obstetric history <0.001
 Nulliparous 123 (37.1) 46646 (40.5)
 Prior vaginal delivery only 92 (27.7) 49769 (43.2)
 Prior cesarean only 43 (13.0) 8827 (7.7)
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No. (%) in Patients With Severe
Maternal Morbidity, n=332
No. (%) in Patients Without Severe
Maternal Morbidity, n=115,156
P†
 Prior cesarean and vaginal 74 (22.3) 9885 (8.6)
Any hypertension 133 (40.1) 13133 (11.4) <0.001
Diabetes mellitus <0.001
 None 265 (79.8) 106430 (92.5)
 Gestational 47 (14.2) 6951 (6.0)
 Pregestational 20 (6.0) 1712 (1.5)
Anticoagulant use during pregnancy 22 (6.6) 895 (0.8) <0.001
Multiple gestation 30 (9.0) 2785 (2.4) <0.001
Polyhydramnios 7 (2.1) 933 (0.8) 0.02
Oligohydramnios 15 (4.5) 4684 (4.1) 0.67
Placenta previa 20 (6.0) 447 (0.4) <0.001
Placenta accreta 41 (12.4) 116 (0.1) <0.001
Placental abruption 24 (7.2) 906 (0.8) <0.001
PROM/preterm PROM 19 (6.0) 5983 (5.3) 0.56
GBS status <0.001
 Negative 125 (37.7) 68792 (59.7)
 Positive 51 (15.4) 24335 (21.1)
 Unknown 156 (47.0) 22029 (19.1)
Neonatal characteristics (on maternal level, according to first born in multiple gestations)
Presentation at delivery <0.001
 Vertex 272 (82.4) 109421 (95.3)
 Breech 47 (14.2) 4796 (4.2)
 Non-breech malpresentation 11 (3.3) 656 (0.6)
Gestational age at delivery, weeks <0.001
 230–276 28 (8.4) 1055 (0.9)
 280–336 57 (17.2) 3508 (3.1)
 340–366 82 (24.7) 8871 (7.7)
 370–376 34 (10.2) 10395 (9.0)
 380–386 32 (9.6) 20311 (17.6)
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No. (%) in Patients With Severe
Maternal Morbidity, n=332
No. (%) in Patients Without Severe
Maternal Morbidity, n=115,156
P†
 390–396 52 (15.7) 37553 (32.6)
 400–406 30 (9.0) 23832 (20.7)
 410–416 16 (4.8) 8981 (7.8)
 ≥420 1 (0.3) 651 (0.6)
Size for gestational age <0.001
 Small 53 (16.0) 10624 (9.2)
 Appropriate 249 (75.2) 95466 (82.9)
 Large 29 (8.8) 9048 (7.9)
PROM, premature rupture of membranes; GBS, group B streptococcus.
*
Severe maternal morbidity defined as a score of at least 8 based on the system of Geller et al.4
†
Based on the chi-square or Fisher’s exact test.
‡
Race or ethnicity as reported in the chart.
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Table 3
Adjusted Odds Ratios and 95% Confidence Intervals of Patient Characteristics Associated With Severe
Maternal Morbidity*
Patient Characteristic Adjusted Odds Ratio 95% CI Risk Score Points†
Age ≥ 35 years 1.70 1.31 2.21 2
Cigarette use during pregnancy 1.44 1.06 1.96 1
Government-assisted insurance 1.56 1.23 1.98 1
Obstetric history (referent: prior vaginal delivery only)
 Nulliparous 1.38 1.04 1.83 1
 Prior cesarean only 1.99 1.35 2.95 2
 Prior cesarean and vaginal 2.12 1.52 2.95 2
Any hypertension 3.36 2.61 4.32 4
Diabetes mellitus (referent: no diabetes mellitus)
 Gestational 2.07 1.49 2.88 2
 Pregestational 1.63 1.00 2.64 2
Antenatal anticoagulant use 5.21 3.27 8.32 5
Placenta accreta 58.11 36.84 91.64 13
Placental abruption 1.92 1.14 3.24 2
Gestational age at delivery (referent: 390–396 weeks)
 230–276 9.10 5.52 15.02 7
 280–336 4.66 3.08 7.06 5
 340–366 3.15 2.17 4.58 4
 370–376 1.52 0.97 2.36 1
 380–386 0.97 0.62 1.51 0
 400–406 1.09 0.69 1.72 0
 410–416 1.60 0.90 2.82 1
 ≥420 1.41 0.19 10.21 1
CI, confidence interval.
*
Severe maternal morbidity defined as a score of at least 8 based on the system of Geller et al.4
†
Based on dividing each beta by 0.322, the smallest significant beta (corresponds to nulliparous), and rounding to the nearest integer.
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